Obstet Gynecol Sci.  2022 Mar;65(2):125-132. 10.5468/ogs.21322.

Contraception in the COVID-19 pandemic: recommendations from the Korean society of contraception and reproductive health

• Lee JH
• Song JY
• Yi KW
• Kim JJ
• Hwang KR
• Shin JH
• Lee JY
• Chae HD

• KMID: 2527264
• DOI: http://doi.org/10.5468/ogs.21322

Abstract

Coronavirus disease 2019 (COVID-19) is associated with a systemic inflammatory response that activates coagulation in symptomatic patients. In addition, a rare form of thrombosis has been reported in people who received the COVID-19 vaccine, most of whom were women younger than 50 years of age. Considering that hormonal contraceptive methods widely used by women of childbearing age increase the risk of thrombosis, the development of guidelines for the use of hormonal contraceptives in the era of the COVID-19 pandemic is necessary. In this context, the Korean Society of Contraception and Reproductive Health provides guidelines for issues regarding contraception and reproductive health during the pandemic.

Keyword

COVID-19; COVID-19 vaccines; Contraception; Contraceptives; oral; combined; Long-acting reversible contraception

Reference

References

1. World Health Organization. Pulse survey on continuity of essential health services during the COVID-19 pandemic: interim report 27 August 2020 [Internet]. Geneva (CH): World Health Organization;c2020. [cited 2021 Sep 15]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2020.1 .

2. Bietsch K, Williamson J, Reeves M. Family planning during and after the West African Ebola crisis. Stud Fam Plann. 2020; 51:71–86.

3. Campbell AM. An increasing risk of family violence during the COVID-19 pandemic: strengthening community collaborations to save lives. Forensic Science International: Reports. 2020; 2:100089.

4. Cohen MA, Powell AM, Coleman JS, Keller JM, Livingston A, Anderson JR. Special ambulatory gynecologic considerations in the era of coronavirus disease 2019 (COVID-19) and implications for future practice. Am J Obstet Gynecol. 2020; 223:372–8.

5. Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID-19. Am J Hematol. 2020; 95:1578–89.

6. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020; 18:1995–2002.

7. Tom S. Thrombosis with thrombocytopenia syndrome (TTS) following Janssen COVID-19 vaccine [Internet]. Atlanta (GA): Centers for Disease Control and Prevention;c2021. [cited 2021 Oct 10]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-04-23/03-COVID-Shimabukuro-508.pdf .

8. European Medicines Agency. VAXZEVRIA/COVID-19 Vaccine AstraZeneca: link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia [Internet]. Amsterdam (NL): European Medicines Agency;c2021. [cited 2021 Oct 10]. Available from: https://www.ema.europa.eu/en/documents/dhpc/directhealthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca_en-0.pdf .

9. American Society of Reproductive Medicine. Patient management and clinical recommendations during the coronavirus (COVID-19) pandemic [Internet]. Birmingham (AL): ASRM;c2020. [cited 2021 Oct 10]. Available from: https://www.asrm.org/globalassets/asrm/asrm-content/news-and-publications/covid-19/covidtaskforce.pdf .

10. European Society of Human Reproduction and Embryology. Coronavirus COVID-19: ESHRE statement on pregnancy and conception [Internet]. Strombeek-Bever (BE): ESHRE;c2021. [cited 2021 Oct 10]. Available from: https://www.eshre.eu/Europe/Position-statements/COVID19 .

11. Lambalk C, van Wely M, Kirkegaard K, Williams A, de Geyter CJHR. Safety first-assisted human reproduction second. Human Reproduction. 2020; 35:741–2.

12. Stanley KE, Thomas E, Leaver M, Wells D. Coronavirus disease-19 and fertility: viral host entry protein expression in male and female reproductive tissues. Fertil Steril. 2020; 114:33–43.

13. Gonzalez DC, Khodamoradi K, Pai R, Guarch K, Connelly ZM, Ibrahim E, et al. A systematic review on the investigation of SARS-CoV-2 in Semen. Res Rep Urol. 2020; 12:615–21.

14. Kotlyar AM, Grechukhina O, Chen A, Popkhadze S, Grimshaw A, Tal O, et al. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021; 224:35–53e3.

15. Veiga A, Gianaroli L, Ory S, Horton M, Feinberg E, Penzias A. Assisted reproduction and COVID-19: a joint statement of ASRM, ESHRE, and IFFS. Fertil Steril. 2020; 114:484–5.

16. World Health Organization. Report of a WHO technical consultation on birth spacing [Internet]. Geneva (CH): World Health Organization;c2021. [cited 2021 Oct 10]. Available from: https://apps.who.int/iris/bitstream/handle/10665/69855/?sequence=1 .

17. Makins A, Arulkumaran S; FIGO Contraception and Family Planning Committee. The negative impact of COVID-19 on contraception and sexual and reproductive health: could immediate postpartum LARCs be the solution? Int J Gynaecol Obstet. 2020; 150:141–3.

18. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive USE, 2016. MMWR Recomm Rep. 2016; 65:1–103.

19. Centers for Disease Control and Prevention. Ensuring access to family planning Services during COVID-19: a summary of CDC’s family planning recommendations for healthcare providers [Internet]. Atlanta (GA): CDC;c2020. [cited 2021 Sep 15]. Available from: https://www.cdc.gov/reproductivehealth/contraception/pdf/FP-and-Covid-19-Fact-Sheet_Final.pdf .

20. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339:b2921.

21. Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013; 87:93–100.

22. Dinger J, Möhner S, Heinemann K. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception. 2016; 93:378–85.

23. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012; 366:2257–66.

24. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002; 65:187–96.

25. Dinger JC, Bardenheuer K, Assmann A. International active surveillance study of women taking oral contraceptives (INAS-OC Study). BMC Med Res Methodol. 2009; 9:77.

26. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception. 2007; 75:328–36.

27. Servante J, Swallow G, Thornton JG, Myers B, Munireddy S, Malinowski AK, et al. Haemostatic and thromboembolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth. 2021; 21:108.

28. Rabinovich A, Abdul-Kadir R, Thachil J, Iba T, Othman M, Erez O. DIC in obstetrics: diagnostic score, highlights in management, and international registry-communication from the DIC and Women’s Health SSCs of the International Society of Thrombosis and Haemostasis. J Thromb Haemost. 2019; 17:1562–6.

29. International Federation of Gynaecology and Obstetrics. FIGO committee on contraception and family planning statement on COVID-19 and pregnancy [Internet]. London (UK): FIGO;c2021. [cited 2021 Oct 10]. Available from: https://www.figo.org/covid-19-contraception-family-planning .

30. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145–7.

31. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of COVID-19 in the young. N Engl J Med. 2020; 382:e60.

32. Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llaneza P, Mendoza N, et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de trombosis y hemostasia. Maturitas. 2020; 137:57–62.

33. Cagnacci A, Bonaccorsi G, Gambacciani M; board of the Italian Menopause Society. Reflections and recommendations on the COVID-19 pandemic: should hormone therapy be discontinued? Maturitas. 2020; 138:76–7.

34. Seeland U, Coluzzi F, Simmaco M, Mura C, Bourne PE, Heiland M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020; 18:369.

35. Lee JH, Kim YC, Cho SH, Lee J, You SC, Song YG, et al. Effect of sex hormones on coronavirus disease 2019: an analysis of 5,061 laboratory-confirmed cases in South Korea. Menopause. 2020; 27:1376–81.

36. Mauvais-Jarvis F, Klein SL, Levin ER. Estradiol, progesterone, immunomodulation, and COVID-19 outcomes. Endocrinology. 2020; 161:bqaa127.

37. Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash YS, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2020; 318:L1280–1.

38. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost. 2020; 120:876–8.

39. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016; 94:678–700.

40. Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ. 2012; 344:e2990.

41. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021; 384:2092–101.

42. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021; 384:1964–5.

43. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007; 44:62–9.

44. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol. 1987; 157(4 Pt 2):1042–8.

45. Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie. 2021; 41:184–9.

46. Korea Centers for Disease Control and Prevention. Vaccination in pregnant women [Internet]. Osong (KR): Korea Centers for Disease Control and Prevention;c2021. [cited 2021 Oct 10]. Available from: http://kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&act=view&list_no=717155 .

47. Centers for Disease Control and Prevention. COVID-19 vaccines while pregnant or breastfeeding [Internet]. Atlanta (GA): CDC;c2021. [cited 2021 Oct 11]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html .

48. World Health Organization. Update on WHO interim recommendations on COVID-19 vaccination of pregnant and lactating women [Internet]. Geneva (CH): World Health Organization;c2021. [cited 2021 Oct 10]. Available from: https://cdn.who.int/media/docs/default-source/2021-dha-docs/update-on-who-interim-recommendations-on-c-19-vaccination-for-pregnant-and-lactating-women-70-.pdf .